Indaptus Therapeutics is trading 14.02% up at $1.22 after its August 13, 2026 second-quarter report highlighted sharply narrower losses and a strategic shift toward neurology and alternatives following the Decoy20 trial halt.
- Cash and short-term investments totaled $11.6 million.
- The company has no active clinical development programs and is evaluating strategic alternatives.
- The move follows $1.07 at the August 14 close; major indexes were nearly flat on August 17, making the update the clearest catalyst.